Fuse Oncology

What Fuse Oncology does

Fuse Oncology is a US-based, private SaaS company founded in 2021 as a spin-out of Cone Health that sells an AI-enabled software platform to radiation-oncology practices, hospitals, and multi-site oncology networks. Its commercial proposition is built around automating the clinical and administrative workflow specific to radiation oncology — documentation, charge capture, treatment planning, authorization, and operational analytics — across the heterogeneous OIS (ARIA, MOSAIQ) and EMR environments used by its customers. The company reports that S!GNAL alone has surfaced $219M+ in corrected charges for its customer base (with a separate homepage metric citing $168M) and that FuseDocs saves clinicians 40+ minutes per patient in documentation time, while targeting a reduction in time-to-treatment from an industry average of 29 days toward 24 hours.

The platform is modular: the underlying Fuse Platform and Syntyant interoperability layer unify EMR, OIS, and treatment-planning data; FuseDocs applies generative AI to consult-note generation; S!GNAL combines a rules-based engine with NLP to predict CPT codes and flag discrepancies; FuseRx optimizes treatment-plan selection against hospital and clinician templates; Auth+ uses predictive models to pre-authorize procedures; and FuseAnalytics surfaces real-time operational metrics across single and multi-site deployments. Fuse documents AI capabilities spanning generative AI, NLP, predictive analytics, anomaly detection, process automation, and optimization, and has a Head of Applied AI plus a distributed engineering team that publicly relies on Anthropic Claude frontier models for development.

Commercially, Fuse sells on a quote-based, multi-year enterprise SaaS basis under Master Services Agreements with Business Associate Agreements for HIPAA compliance, supported by adjacent clinical consulting and quarterly data-review engagements. Go-to-market is sales-led and US-only, anchored by a direct "Request a Demo" motion, sustained presence at the ASTRO annual conference (booth #1618 in 2023, ASTRO 2025 showcase), and a Clinical Liaison Council of senior radiation oncologists from Inova Schar, Carilion Clinic, Advent Health, and others. Disclosed outside capital totals ~$11.86M across a 2021 seed/2022 round from First Launch Capital Fund and a 2023 strategic round led by Cone Health and Northeast Georgia Health System; revenue and headcount are not publicly disclosed.

Name

Fuse Oncology

Legal name

Fuse Oncology, Inc.

Website

https://fuseonc.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Fuse Oncology is a US-based private SaaS company that sells an AI-enabled, interoperable software platform to radiation-oncology practices, hospitals, and multi-site oncology networks, automating clinical documentation, charge capture, treatment planning, authorization, and analytics.

Ownership category

akta.pro rank

Product category

Radiation Oncology Healthcare Software

NAICS

Computer Systems Design and Related Services (54151), Diagnostic Imaging Centers (621512), Custom Computer Programming Services (541511), Software Publishers (51321)

SIC

Services-Computer Programming Services (7371), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim) (HLAHABAH), Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD), Oncology Telemedicine Platforms (HLALAGAH)

Keywords

• Radiation oncology software
• Oncology information systems
• Clinical documentation AI
• Charge capture software
• Healthcare interoperability platform

Headquarters

HQ city

Greensboro

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Fuse Platform SaaS Subscriptions: Recurring SaaS subscriptions for the integrated Fuse software suite (FuseDocs, S!GNAL, FuseRx, FuseAnalytics, Auth+) sold to radiation oncology practices, hospitals and health systems; customer agreements governed by Master Services Agreements with separate order forms.
2. Clinical Consulting & Professional Services: Adjacent professional services including clinical consulting engagements to define and standardize service-line rules, change management support, and quarterly data review meetings with operational leaders (referenced for S!GNAL and FuseAnalytics engagements).

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

Fuse Oncology sells a vertically integrated, AI-enabled SaaS suite for radiation oncology practices and health systems. Its core offering is the Fuse Platform — an interoperable data layer that unifies EMR, OIS (ARIA, MOSAIQ), and treatment planning systems — on top of which it delivers modular applications for clinical documentation (FuseDocs), charge capture and billing integrity (S!GNAL), treatment plan selection (FuseRx), predictive authorization (Auth+), and operational analytics (FuseAnalytics).

Product overview

Fuse Oncology delivers a platform-plus-modules architecture: the core Fuse Platform (an AI-enabled, interoperable SaaS layer that unifies EMR, OIS, and treatment-planning data, underpinned by the Syntyant interoperability layer) hosts a suite of modular RadOnc applications. The named modules include FuseRX for treatment-plan optimization, Auth+ for predictive procedure authorization, FuseDocs for generative-AI clinical documentation, S!GNAL for AI-powered charge capture and billing intelligence, and FuseAnalytics for real-time operational analytics. Together they enable clinicians and administrators to compress the consult-to-treatment timeline from a typical 3–4 weeks toward Fuse's stated 24-hour goal.

Differentiator

Problem solved

Functional benefit

Brands

• S!GNAL: Charge capture review and billing analytics solution for radiation oncology that flags missing, incorrect, or inconsistent charges in real time.
• FuseDocs
• FuseRX
• FuseAnalytics
• Auth+
• Syntyant

Products and services

• Fuse Platform The underlying AI-enabled, interoperable SaaS platform that powers Fuse Oncology's radiation oncology suite. It eliminates data fragmentation, unifies EMR/OIS/Planning-system data via the Syntyant interoperability layer, and hosts the company's modular applications (FuseDocs, S!GNAL, FuseRx, FuseAnalytics, Auth+) for radiation oncologists, medical physicists, radiation therapists, and practice administrators.
• FuseRx Treatment planning module that optimizes care plans using patient data, hospital preferences, and clinician templates, enabling rapid selection and customization of the right plan in minutes. Built for radiation oncologists and treatment planners seeking to reduce planning time and standardize care across clinicians.
• Auth+ Provider authorization module that goes beyond standard authorization by using historical data, provider information, and predictive models to pre-authorize procedures and reduce patient wait times. Targeted at radiation oncology practices seeking to compress the time-to-treatment timeline.
• FuseDocs Generative AI-powered consult workspace that activates disease-specific workflows for radiation oncology, pulling data from EMR, OIS, and scanned documents to auto-generate complete consult notes including the History of Present Illness, saving clinicians 40+ minutes per patient. Targets radiation oncologists and clinical staff burdened by template-based documentation.
• S!GNAL AI-powered charge-capture review and billing-intelligence solution that uses a rules-based engine and natural language processing to identify missing, incorrect, or inconsistent charges across OIS/EMR data in real time, preventing revenue leakage, reducing audit exposure, and preventing up to 35% of billing denials. Serves radiation oncology practices, hospital systems, and multi-site networks.
• FuseAnalytics Real-time analytics module with configurable dashboards, advanced filtering, and role-specific widgets that surfaces key radiation oncology metrics such as time-to-treat, bottlenecks, revenue, identified errors, treatment volumes, and new starts. Built for practice administrators and operational leaders.
• Syntyant Interoperable Platform Interoperability platform that provides seamless connectivity among diverse healthcare technologies — EMR, OIS (ARIA, MOSAIQ), and treatment planning systems — to accelerate delivery of care and aggregate data into a unified view across heterogeneous databases and time zones.

Quantifiable outcome

• $219,246,834 in charges corrected across Fuse Oncology customers nationwide via S!GNAL
• +5 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability9 records

Feature7 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• Cone HealthflagshipStrategic or Co-development Partner · 1 January 2021Cone Health (Greensboro, NC) is the originating health system from which Fuse Oncology was spun out in 2021 via Cone Ventures. Cone Health developed and utilized the underlying S!GNAL technology over several years prior to commercialization, and remains a flagship reference customer and partner. The Fuse Clinical Liaison Council Chair, Dr. Matt Manning, is a radiation oncologist at Cone Health, and Skip Hislop (VP of Oncology at Cone) provides public testimonial about Fuse's impact on Cone's practice. Cone Health/Cone Ventures also facilitated FLCF's investment model referenced as a regional template for employer-backed spin-outs.
• ARIA (OIS platform)coreTechnology or IntegrationARIA is one of the OIS platforms (alongside MOSAIQ) explicitly referenced in Fuse's S!GNAL and FuseAnalytics materials as a system Fuse integrates with to aggregate data across disparate OIS/EMR databases into a unified dashboard for radiation oncology charge capture and analytics.
• MOSAIQ (OIS platform)coreTechnology or IntegrationMOSAIQ is one of the OIS platforms (alongside ARIA) explicitly referenced in Fuse's S!GNAL and FuseAnalytics materials as a system Fuse integrates with to aggregate data across disparate OIS/EMR databases into a unified dashboard for radiation oncology charge capture and analytics.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Market position

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/fuse-onc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fuse Oncology